Portfolio Rapha Capital Management

Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer

By Kevin SlawinJuly 20, 2018February 4th, 2021No Comments

Poseida Therapeutics
Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer
July 20, 2018

Previous PostPoseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
Next PostNuMat Technologies Closes $12.4M Funding Round to Accelerate Commercialization of Molecularly Engineered Products

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions